APA (7th ed.) Citation

V, O., S, R., M, E., A, A., M, M., L, M., . . . J, D. (2021). Factors associated with the clinical outcome of patients with relapsed/refractory CD19+ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy. Journal for immunotherapy of cancer, 9(12), . https://doi.org/10.1136/jitc-2021-003644

Chicago Style (17th ed.) Citation

V, Ortiz-Maldonado, et al. "Factors Associated with the Clinical Outcome of Patients with Relapsed/refractory CD19+ Acute Lymphoblastic Leukemia Treated with ARI-0001 CART19-cell Therapy." Journal for Immunotherapy of Cancer 9, no. 12 (2021). https://doi.org/10.1136/jitc-2021-003644.

MLA (9th ed.) Citation

V, Ortiz-Maldonado, et al. "Factors Associated with the Clinical Outcome of Patients with Relapsed/refractory CD19+ Acute Lymphoblastic Leukemia Treated with ARI-0001 CART19-cell Therapy." Journal for Immunotherapy of Cancer, vol. 9, no. 12, 2021, https://doi.org/10.1136/jitc-2021-003644.